Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM199 dose-escalation and expansion study in preterm preeclampsia
2026-527887-33-00Phase 2Authorised
- Sponsor
- DiaMedica Therapeutics
- Start
- Oct 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of rinvecalinase alfa in preeclampsia (2 arms), sponsored by DiaMedica Therapeutics. Primary endpoints: Safety and tolerability of DM199, Umbilical cord blood DM199 levels and 2 more. Planned start Oct 2026; status: authorised.
02
Drugs
rinvecalinase alfa
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2026-527887-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527887-33-00.